Logo Annals of Transplantation Logo Annals of Transplantation Logo Annals of Transplantation

30 December 2011

Immunosuppressive regimens containing generic mycophenolate mofetil (Myfenax) in de novo renal transplant recipients – preliminary results of 6-month observation

Bolesław RutkowskiACDE, Beata BzomaBCEF, Alicja Dębska-ŚlizieńABCDE, Andrzej ChamieniaBDE

Ann Transplant 2011; 16(4): 74-80 :: ID: 882222


Background: The aim of the findings presented below is to show the preliminary outcomes of transplantation in patients treated with the generic formulation of mycophenolate mofetil (Myfenax, Teva).
Material/Methods: Over the past 2 years 34 patients received generic mycophenolate mofetil (Myfenax) after renal transplantation at the Gdansk Transplantology Center. During the same time period another 127 kidney transplantations were performed in our Department and these patients were treated with other formulations of mycophenolate (CellCept, Myfortic or Mycophenolate mofetil Apotex) as a part of the immunosuppressive scheme. Fifteen of the Myfenax patients received a pair of kidneys from the same donor and received original mycophenolate mofetil Cell-Cept.
Results: The outcomes of the renal transplants in both groups (Myfenax vs. pair) were good; with satisfactory function of grafts, and no instances of graft loss were reported. There was no difference in the incidence of acute renal graft rejection (AR) in either group. Moderate adverse reactions to immunosupression were observed in both groups.
On the other hand, a comparison between the 34 patients with Myfenax and the 127 other patients with other formulations of mycophenolate revealed no differences in the incidence of AR, delayed graft function (DGF), graft loss and death.
Conclusions: There were no differences in the incidence of AR, DGF, graft loss and death in patients with Myfenax vs. original CellCept and other formulations of mycophenolate.
In order to confirm its complete biological and pharmacokinetic equivalence with the reference medicine, long-term, randomized observations carried out on larger renal transplant patients groups are needed.

Keywords: immunosupressive therapy, kidney tranplantation, mycophenolate

Add Comment 0 Comments

In Press

Original article  

Engraftment Syndrome in Autologous Hematopoietic Stem Cell Transplant Patients: Incidence, Associated Risk ...

Ann Transplant In Press; DOI: 10.12659/AOT.944043  

Original article  

Comparative Study of Acute Kidney Injury in Liver Transplantation: Donation after Circulatory Death versus ...

Ann Transplant In Press; DOI: 10.12659/AOT.944077  

Original article  

Abnormal Liver Biopsies of Donor Grafts in Pediatric Liver Transplantation: How Do They Fare?

Ann Transplant In Press; DOI: 10.12659/AOT.944245  

Original article  

Kidney After Lung Transplants or Combined Kidney–Lung Transplantation: A Single-Center Retrospective Cohort...

Ann Transplant In Press; DOI: 10.12659/AOT.944049  

Most Viewed Current Articles

05 Apr 2022 : Original article   12,431

Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver Transplantation

DOI :10.12659/AOT.935604

Ann Transplant 2022; 27:e935604

22 Nov 2022 : Original article   9,292

Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...

DOI :10.12659/AOT.937988

Ann Transplant 2022; 27:e937988

12 Jan 2022 : Original article   8,874

Risk Factors for Developing BK Virus-Associated Nephropathy: A Single-Center Retrospective Cohort Study of ...

DOI :10.12659/AOT.934738

Ann Transplant 2022; 27:e934738

15 Mar 2022 : Case report   6,666

Combined Liver, Pancreas-Duodenum, and Kidney Transplantation for Patients with Hepatitis B Cirrhosis, Urem...

DOI :10.12659/AOT.935860

Ann Transplant 2022; 27:e935860

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Annals of Transplantation eISSN: 2329-0358
Annals of Transplantation eISSN: 2329-0358